Track topics on Twitter Track topics that are important to you
Q BioMed Inc (OTCQB: QBIO) CEO Denis Corin tells Proactive Investors the commercial-stage biotech is taking the final step in the approval process of its bone pain relief treatment, the "spearhead'" of Q BioMed's pipeline.
Corin says Q BioMed has submitted a supplemental regulatory filing to the US FDA for the approval of a new manufacturing facility in Texas. Approval will allow the facility to manufacture its Strontium Chloride Sr8 drug.
Cobin says with the approval to manufacture the drug, the company expects to be in the US$2mln to US$3mln revenue point with the opportunity to grow into a US$100mln market in the next few years.NEXT ARTICLE
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...
An anesthesiologist (US English) or anaesthetist (British English) is a physician trained in anesthesia and perioperative medicine. Anesthesiologists are physicians who provide medical care to patients in a wide variety of (usually acute) situations. ...